Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 15, 2011

Denosumab Superior for Preventing Skeletal Complications in Advanced Prostate Cancer

The Lancet

 

Additional Info

The Lancet
Denosumab Versus Zoledronic Acid for Treatment of Bone Metastases in Men With Castration-Resistant Prostate Cancer: A Randomised, Double-Blind Study
Lancet 2011 Mar 05;377(9768)813-822, K Fizazi, M Carducci, M Smith, R Damião, J Brown, L Karsh, P Milecki, N Shore, M Rader, H Wang, Q Jiang, S Tadros, R Dansey, C Goessl

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.


Further Reading